Company profile: PrognomiQ
1.1 - Company Overview
Company description
- Provider of multi-omics liquid biopsy and proteomic profiling for early disease detection. Offers a platform integrating proteomics, genomics, and metabolomics for early-stage cancers such as lung and pancreatic, large-scale plasma proteomics for biomarker discovery, glycoproteome detection across cancer cohorts, and a multi-omics product pipeline for early detection and treatment of cancer.
Products and services
- Multi-omics Liquid Biopsy Platform: Custom-engineered platform combining proteomics, genomics, and metabolomics to enable early-stage detection of diseases such as lung and pancreatic cancer using multi-omics data
- Multi-omics Product Pipeline: Modular pipeline develops products based on multi-omics data for early detection and treatment of cancer, building test products informed by integrated omic analyses
- Proteomics Profiling: High-throughput method for large-scale plasma proteomics studies that enable biomarker discovery across various diseases, conducting expansive protein profiling in plasma samples
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PrognomiQ
Isobionics
HQ: The Netherlands
Website
- Description: Provider of isoprenoid-based flavor and fragrance ingredients produced via a proprietary biotechnology process for the food, beverage, flavor and fragrance markets, delivering higher quality and purity at lower production cost. Portfolio includes Natural Nootkatone, beta-Caryophyllene, Valencene, (-)-alpha-Bisabolol, alpha-Bisabolene, and beta-Bisabolene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Isobionics company profile →
Avia Biosystems
HQ: United States
Website
- Description: Provider of biophysical and biochemical characterization instruments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avia Biosystems company profile →
Nextal Biotech
HQ: United States
Website
- Description: Provider of products designed for experimental crystallization needs, offering plates with grease-free, independent, screwable crystallization supports.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nextal Biotech company profile →
Akonni Biosystems
HQ: United States
Website
- Description: Provider of genetic testing and molecular diagnostic solutions, including TruDiagnosis microarray-based multiplex analysis of infectious diseases; TruTip DNA/RNA extraction and the Automated Workstation; TruDx2000 near point-of-care amplification/detection platform; TruDx3000 sample-in, answer-out testing system; and Lab-on-a-Film microfluidic disposables for low-cost diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akonni Biosystems company profile →
Sirigen
HQ: United Kingdom
Website
- Description: Provider of light-harvesting polymer materials and High Sensitivity Fluorescence (HSF) technology for diagnostic and life science applications. Offers HSF to enhance signals, lower detection limits and improve multiplexing; Brilliant Violet dyes for violet lasers and flow cytometry; and solutions for immunoassays/ELISA, biomarkers/proteomics, and lateral flow/point-of-care with simplified sample processing and instrumentation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirigen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PrognomiQ
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PrognomiQ
2.2 - Growth funds investing in similar companies to PrognomiQ
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PrognomiQ
4.2 - Public trading comparable groups for PrognomiQ
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →